Article: Highly diastereoselective synthesis of 3-indolylglycines via an asymmetric oxidative heterocoupling reaction of a chiral nickel(ii) complex and indoles.[show abstract] [hide abstract]
ABSTRACT: The asymmetric synthesis of 3-indolylglycine derivatives was achieved by an oxidative heterocoupling reaction. This method for the selective C-3 functionalization of unprotected indoles with the chiral equivalent of a nucleophilic glycine nickel(ii) complex afforded adducts with high diastereoselectivities. The decomposition of adducts readily afforded 3-indolylglycine derivatives in high yields.Chemical Communications 02/2013; 49(25):2575-7. · 6.17 Impact Factor
Article: [Analysis of learning process of video-assisted minimally invasive esophagectomy for thoracic esophageal carcinoma].[show abstract] [hide abstract]
ABSTRACT: To evaluate the learning process of video-assisted minimally invasive esophagectomy(MIE). One hundred consecutive patients with thoracic esophageal carcinoma were treated by a same team of surgeons, and were divided into 3 groups in chronological order. The former two groups both consisted of 25 patients with thoracoscopy plus laparotomy. The remaining 50 patients were enrolled in the third group with thoracoscopy plus laparoscopy. Clinicopathological data including operative time, blood loss, protection of normal structures, complications, length of ICU stay, postoperative stay, and lymph nodes harvest, were collected and compared between groups. Procedures were accomplished successfully in 96 patients. Only 4 cases were converted to open thoracotomy and none to laparotomy. The median operative time was 310 min and blood loss was 200 ml. The median number of lymph node harvest was 22. The overall complication rate was 50%. Comparison of first two groups revealed that significant differences existed in the preservation rate of arch of azygos vein (P=0.010), bronchial vessels (P=0.038), and exposure rate of thoracic part of left recurrent laryngeal nerve(P=0.048). Comparison of the former and latter 50 patients revealed that significant differences existed in thoracic operative time (P<0.001), blood loss (P=0.025), preservation rate of arch of azygos vein(P=0.001) and bronchial vessels(P<0.001), the number of lymph node harvest in thoracoscopy(P=0.022) and in left recurrent laryngeal nerve chain(P<0.001), and exposure rate of initiate part of left recurrent laryngeal nerve (P=0.002). The learning curve of MIE is long and beginners should proceed step by step.Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 09/2012; 15(9):918-21.
Jinming Zhao, Zhihua Zhu, Xiaodong Su, Xu Zhang, Zhaohong Wu, Gangdong Chen, Gefei Wang, Tiehua Rong[show abstract] [hide abstract]
ABSTRACT: ObjectiveThe aim of our study was to investigate the clinical significance of Smac (second mitochondria-derived activator of caspase) expression on non-small cell lung cancer (NSCLC). MethodsThe expression of Smac was evaluated on RNA and protein level in tumor tissues. The expression of Smac mRNA was examined by RT-PCR in 59 samples of tumor tissues and matched normal lung tissues. The expression of Smac protein was examined by IHC in 213 cancer tissues. ResultsThe positive rate of Smac mRNA was found in 59.3% of cancer tissues, but only in 30.5% of matched normal tissues (P < 0.05). The positive rate of Smac protein was 76.5%. The expression of Smac in stage II disease was significantly higher than that in stage I disease (P = 0.001). The survival of patients with Smac overexpression was significantly shorter than those who were negative. ConclusionSmac might be involved in the progression of NSCLC, the biologic significance of Smac in primary lung cancer needs further study. Key wordsSmac–non-small cell lung cancer (NSCLC)–RT-PCR–IHCThe Chinese-German Journal of Clinical Oncology 04/2012; 10(5):249-251.
Article: Clinical research regarding the ratio of lymph node metastasis and the reasonable extent of lymphadenectomy in middle third thoracic esophageal squamous cell carcinomaMing-ran Xie, Peng Lin, Xu Zhang, Jie-xin Chen, Yong-bin Lin, Zhe-sheng Wen, Tie-hua Rong, Xiao-dong Li, Jun-ye Wang, Hui Yu[show abstract] [hide abstract]
ABSTRACT: ObjectiveTo explore the extent of lymphadenectomy deemed reasonable by analyzing the influence of the regular pattern and ratio of lymph node metastasis on the prognosis of the patients with middle third thoracic esophageal squamous cell carcinoma. MethodsClinical data from 129 patients with middle third thoracic esophageal squamous cell carcinoma who underwent curative esophagectomy with modern two-field lymphadenectomy were retrospectively analyzed. ResultsThe rate of lymphatic metastasis in EC patients was 56.6% in all groups, and the ratio of lymph node metastasis (RLNM, i.e. positive nodes/total dissected nodes) was 11.3%, with a lymphatic metastasis rate of 43.4% in the superior mediastinum. The most commonly involved regions included the sites around the esophagus, the right recurrent laryngeal nerve and the left-sided blood vessels of stomach, as well as the cardia and the inferior tracheal protuberance. The main factors influencing lymphatic metastasis were the depth of tumor infiltration, differentiation of tumor cells and the size of the tumor. The 5-year survival rate for patients in the groups without lymphatic metastasis, with a RLNM ≤ 20%, and a metastasis ratio > 20% was 50.4%, 31.0% and 6.8%, respectively. The differences were statistically significant among the groups (P = 0.000). ConclusionThe RLNM is one of the key factors affecting the prognosis of EC patients. For conventional therapy for patients with middle third thoracic esophageal carcinoma, modern 2-field lymphadenectomy, including node dissection in the bilateral superior mediastinum, should be performed. Key Wordsesophagus cancer-lymph nodes-metastasis-lymphadenectomyClinical Oncology and Cancer Research 04/2012; 7(1):33-38.
Article: Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.Xiao-qin Zhao, Jing-dun Xie, Xing-gui Chen, Hong May Sim, Xu Zhang, Yong-ju Liang, Satyakam Singh, Tanaji T Talele, Yueli Sun, Suresh V Ambudkar, Zhe-Sheng Chen, Li-wu Fu[show abstract] [hide abstract]
ABSTRACT: Neratinib, an irreversible inhibitor of epidermal growth factor receptor and human epidermal receptor 2, is in phase III clinical trials for patients with human epidermal receptor 2-positive, locally advanced or metastatic breast cancer. The objective of this study was to explore the ability of neratinib to reverse tumor multidrug resistance attributable to overexpression of ATP-binding cassette (ABC) transporters. Our results showed that neratinib remarkably enhanced the sensitivity of ABCB1-overexpressing cells to ABCB1 substrates. It is noteworthy that neratinib augmented the effect of chemotherapeutic agents in inhibiting the growth of ABCB1-overexpressing primary leukemia blasts and KBv200 cell xenografts in nude mice. Furthermore, neratinib increased doxorubicin accumulation in ABCB1-overexpressing cell lines and Rhodamine 123 accumulation in ABCB1-overexpressing cell lines and primary leukemia blasts. Neratinib stimulated the ATPase activity of ABCB1 at low concentrations but inhibited it at high concentrations. Likewise, neratinib inhibited the photolabeling of ABCB1 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner (IC(50) = 0.24 μM). Neither the expression of ABCB1 at the mRNA and protein levels nor the phosphorylation of Akt was affected by neratinib at reversal concentrations. Docking simulation results were consistent with the binding conformation of neratinib within the large cavity of the transmembrane region of ABCB1, which provides computational support for the cross-reactivity of tyrosine kinase inhibitors with human ABCB1. In conclusion, neratinib can reverse ABCB1-mediated multidrug resistance in vitro, ex vivo, and in vivo by inhibiting its transport function.Molecular pharmacology 04/2012; 82(1):47-58. · 4.53 Impact Factor